Document Type
Article Presentation
Original Publication Date
2025
Date of Submission
December 2025
Abstract
The drug studied was Ozanimod which is an oral sphingosine-1 -phosphate (S1P) receptor modulator, and was experimented in patient suffering from Ulcerative colitis (UC) who weren’t exposed to biological or Janus Kinase (JAK) inhibitors previously. The effects of Ozanimod treatment led to promising results such as greater rates of clinical remission, endoscopic movement as well as histologic remission as compared to the placebo group. The safety profile neither improved nor declined with regard to the side effects of previously conducted experiments with Ozanimod, thus had no serious concerns observed. Ozanimod treatment thus could strongly help patients with moderate to severe UC and could be considered as an advanced therapy as the first-line of action to treat UC.
Rights
© The Author(s)